Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

Sponsor
First Hospital of China Medical University
Study ID
NCT05863273
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast — DRUG
    Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.

Study Details

This is a multicenter, one-arm, prospective, observational study，intended to assess evaluation of efficacy and safety of Apremilast in Chinese patients with moderate-to-severe plaque psoriasis。During this study, it is expected to collect data at at baseline and weeks 2, 6, 10, 16, and 20 after treatment。

Key Dates

First listed
May 18, 2023
Start date
May 22, 2023
Status verified
Mar 2025
Primary completion
Feb 10, 2025
Completion
Mar 10, 2025

Study Design

Enrollment
360 participants (actual)

Arms

  • Arm: Apremilast
    Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.

Primary Outcome Measure

DLQI or PASI improvement [ Time Frame: 16 week ]

Related Studies